{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Acute Leukemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Chronic myeloproliferative disorders (CMPD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Chronic Myelomonocytic Leukemia (CMML)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Essential Thrombocythemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypereosinophilic syndrome (HES)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Systemic mastocytosis (SM)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Myelodysplastic syndromes (MDS)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Myelofibrosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Polycythemia Vera (PV)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"Acute myeloid leukemia (AML), Myelodysplastic Syndromes (MDS): CR=Normalization peripheral blood \\& bone marrow with 5% or less blasts; normo- or hypercellular marrow; Absolute Neutrophil Count (ANC) \\> 1.0 x 10\\^9/L, \\& platelet count \\>100 x 10\\^9/L; or CR marrow=As per CR but platelet count \\< 100 x 10\\^9/L. Agnogenic myeloid metaplasia (AMM) \\& CMML: CR=Absence of signs/symptoms of disease; White blood count between 1 to 10 x 10\\^9/L with no peripheral blasts, promyelocytes, or myelocytes and normalization of bone marrow (\\< 5% blasts in normocellular or hypercellular marrow) for 4+ weeks. PV: CR=normalization of hemoglobin/hematocrit without need for phlebotomies, disappearance all signs/symptoms of disease. HES: CR=disappearance of eosinophilia (\\</=10%), disappearance signs/symptoms of disease. Mastocytosis: CR=disappearance of mast cell infiltrates in affected organs, decrease of serum tyrptase levels to \\<20 ng/ml, \\& disappearance of SM-associated organomegaly.","groups":[{"description":"Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.","id":"OG000","title":"Imatinib Mesylate"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"after 2 months of therapy, up to 1 year.","title":"Number of Participants With a Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"participants"}